Abstract
Background: Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular and neurocognitive complications. GLP-1 receptor agonists (GLP-1 RAs) and SGLT2 inhibitors (SGLT2is) have pleiotropic effects beyond glycemic control, but comparative long-term data on dementia, cardiovascular events, and mortality in older adults are limited. Methods: This retrospective cohort study used the TriNetX US Collaborative Network. Adults ≥60 years with T2DM on metformin plus either GLP-1 RAs or SGLT2is (n=56,211 per cohort after matching, 2014–2020) were propensity-score matched on demographic and clinical characteristics. Five-year outcomes included incident Alzheimer’s disease, vascular dementia, other dementia, dementia-related medication use, NSTEMI, STEMI, and all-cause mortality. Results: After propensity-score matching, GLP-1 RA use was associated with higher risks of Alzheimer’s disease (RR 1.33, 95% CI 1.18–1.48), vascular dementia (RR 1.56, 95% CI 1.39–1.76), other dementia (RR 1.33, 95% CI 1.21–1.47), dementia-related medication initiation, and all-cause mortality (RR 1.11, 95% CI 1.08–1.15) compared with SGLT2is. NSTEMI and STEMI risks did not differ significantly between groups. Conclusions: In older adults with T2DM, SGLT2is were associated with lower risks of dementia, dementia-related medication use, and all-cause mortality compared with GLP-1 RAs in propensity-score matched cohorts. These observational findings are hypothesis-generating and should be confirmed in prospective studies.
| Original language | English (US) |
|---|---|
| Journal | Diabetes and Vascular Disease Research |
| Volume | 23 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1 2026 |
Keywords
- Cardiology
- Dementia
- Diabetes mellitus type 2
- Glucagon-like peptide-1 receptor agonists
- Sodium-glucose cotransporter 2 inhibitors
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Cardiology and Cardiovascular Medicine
Fingerprint
Dive into the research topics of 'Benefits of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide-1 receptor agonists in older patients with type 2 diabetes'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS